Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

BARD(CR) : Bard Announces Agreement to Acquire Medivance, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/25/2011 | 10:15pm CEST

C. R. Bard, Inc. (NYSE: BCR) today announced that it has reached a definitive agreement to acquire Medivance, Inc. for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions, including Hart-Scott-Rodino clearance. Upon completion of the merger, the Medivance organization will become part of Bard Medical division.

Medivance, located in Louisville, Colorado, is the market leader in the field of therapeutic hypothermia. In recent years, accurate manipulation of body temperature to targeted levels has emerged as an effective treatment option for a variety of critically ill patients. The American Heart Association, The American Stroke Association, The Brain Trauma Foundation and various international medical associations have issued therapeutic hypothermia guidelines as the clinical data supporting Targeted Temperature Management? has grown. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Timothy M. Ring, chairman and CEO, commented, "With their unique and proprietary technology, Medivance is the market leader in an emerging and growing space. This merger is a great strategic fit for Bard as Medivance's Targeted Temperature Management? product line is synergistic with our critical care sales call point, and their technology efficiently addresses a large unmet need in a market that is growing double digits. This acquisition represents an important building block for our critical care product offering."

Based on the anticipated completion of the merger in the fourth quarter of 2011, Bard expects the dilution impact to be immaterial to earnings per share in 2011.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2011 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on C R BARD INC
10/14 C R BARD : Judicial Panel on Multidistrict Litigation Issues Order on C.R. Bard
10/12 C R BARD : Stock Performance Review on Medical Supplies Industry -- Microbot Med..
10/11 C R BARD : Bard Declares Quarterly Dividend
09/28 C R BARD : Becton Dickinson offers EU concessions over $24 billion Bard deal
08/31 C R BARD : Receives FDA Premarket Approval of the LUTONIX 035 Drug Coated Balloo..
08/28 C R BARD : Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Ballo..
08/22 EARNINGS REVIEW AND FREE RESEARCH RE : Becton, Dickinson and Co.’s Q3 Adju..
08/11 INSIDER TRADING ACTIVITY C.R. BARD, : BCR) – Insider Sold 23,687 shares o..
08/10 BACTIGUARD : Interim report for Q2 2017
08/08 BARD C R INC /NJ/ : Submission of Matters to a Vote of Security Holders, Other E..
More news
News from SeekingAlpha
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/11 C. R. Bard declares $0.26 dividend
10/09 First meeting of new FDA advisory committee this week
09/26 Most Overbought And Oversold S&P Stocks
09/04 Dividend Income Update August 2017
Financials ($)
Sales 2017 3 929 M
EBIT 2017 1 110 M
Net income 2017 777 M
Finance 2017 70,2 M
Yield 2017 0,32%
P/E ratio 2017 33,36
P/E ratio 2018 29,09
EV / Sales 2017 5,96x
EV / Sales 2018 5,63x
Capitalization 23 493 M
Chart C R BARD INC
Duration : Period :
C R Bard Inc Technical Analysis Chart | BCR | US0673831097 | 4-Traders
Technical analysis trends C R BARD INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 303 $
Spread / Average Target -6,3%
EPS Revisions
Managers
NameTitle
Timothy M. Ring Chairman & Chief Executive Officer
John H. Weiland President, Chief Operating Officer & Director
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC43.94%23 493
MEDTRONIC PLC9.60%105 292
BAXTER INTERNATIONAL41.68%34 681
ZIMMER BIOMET HOLDINGS INC15.99%24 164
HOYA CORPORATION27.19%21 742
TERUMO CORP7.86%15 788